Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Common Equity (2023 - 2025)

Mangoceuticals' Common Equity history spans 3 years, with the latest figure at $15.7 million for Q3 2025.

  • For Q3 2025, Common Equity rose 13.74% year-over-year to $15.7 million; the TTM value through Sep 2025 reached $15.7 million, up 13.74%, while the annual FY2024 figure was $13.9 million, 1699.93% up from the prior year.
  • Common Equity for Q3 2025 was $15.7 million at Mangoceuticals, down from $19.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $20.3 million in Q1 2025 and bottomed at -$958468.0 in Q1 2024.
  • The 3-year median for Common Equity is $13.8 million (2024), against an average of $9.5 million.
  • The largest annual shift saw Common Equity plummeted 125.1% in 2024 before it surged 2212.82% in 2025.
  • A 3-year view of Common Equity shows it stood at $774754.0 in 2023, then skyrocketed by 1699.93% to $13.9 million in 2024, then grew by 12.79% to $15.7 million in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Common Equity are $15.7 million (Q3 2025), $19.2 million (Q2 2025), and $20.3 million (Q1 2025).